CD96 (US20200199227A1 Biosimilar) Recombinant Monoclonal Antibody
-
貨號：CSB-RA004971MB1HU
-
規格：
-
其他：
產品詳情
-
Uniprot No.：
-
基因名：
-
別名：CD96; T-cell surface protein tactile; Cell surface antigen CD96; T cell-activated increased late expression protein; CD antigen CD96
-
反應種屬：Human
-
免疫原：Recombinant Human CD96 protein
-
免疫原種屬：Homo sapiens (Human)
-
標記方式：Non-conjugated
-
克隆類型：Monoclonal
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 -
產品提供形式：Liquid
-
應用說明：Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method. -
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：In stock
-
用途：It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
產品評價
相關產品
靶點詳情
-
功能：May be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response. Promotes NK cell-target adhesion by interacting with PVR present on target cells. May function at a time after T and NK cells have penetrated the endothelium using integrins and selectins, when they are actively engaging diseased cells and moving within areas of inflammation.
-
基因功能參考文獻：
- Lower CD96 expression was also observed in human IL-9(+) compared with IFN-gamma(+) T cells PMID: 29531070
- Blocking CD96 or TIGIT with mAbs has been shown to improve tumor control in mice. PMID: 27620276
- CD96 and CD123 are expressed in bone marrow cells of patients with myelodysplastic syndromes PMID: 26642704
- In the present study we analyzed the expression of four cell surface antigens relevant to human hematopoiesis-CD90, CD96, CD117, and CD123-in bone marrow from pediatric acute myeloid leukemia patients and normal control subjects. PMID: 24751333
- down-regulation of CD96 is an important aspect of HIV-1 pathogenesis and differential expression is related to cell effector functions and HIV-1 disease course. PMID: 23272144
- CD96 could serve as a target structure for effector cell-mediated lysis. PMID: 22879978
- The positive expression of CD96 on bone marrow hematopoietic stem cells in patients with acute leukemia may be associated with primary drug resistance, relapse and progression. PMID: 21729528
- CD96 promotes natural killer (NK) cell adhesion to target cells expressing the poliovirus receptor (PVR), stimulates cytotoxicity of activated NK cells, and mediates acquisition of PVR from target cells. PMID: 15034010
- CD96 is a cell surface marker present on many acute myeloid leukemia leukemic stem cells PMID: 17576927
- CD96-driven adhesion to CD155 may be crucial in developmental processes PMID: 19056733
顯示更多
收起更多
-
相關疾病：C syndrome (CSYN)
-
亞細胞定位：Membrane; Single-pass type I membrane protein.
-
組織特異性：Expressed on normal T-cell lines and clones, and some transformed T-cells, but no other cultured cell lines tested. It is expressed at very low levels on activated B-cells.
-
數據庫鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
